Oaktree Specialty Lending Stock Forecast, Price & News

Oaktree Specialty Lending (NASDAQ:OCSL) Frequently Asked Questions

Is Oaktree Specialty Lending a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oaktree Specialty Lending in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Oaktree Specialty Lending stock.
View analyst ratings for Oaktree Specialty Lending or view top-rated stocks.

How has Oaktree Specialty Lending's stock been impacted by Coronavirus (COVID-19)?

Oaktree Specialty Lending's stock was trading at $4.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCSL stock has increased by 64.0% and is now trading at $7.28.
View which stocks have been most impacted by COVID-19.

When is Oaktree Specialty Lending's next earnings date?

Oaktree Specialty Lending is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Oaktree Specialty Lending.

How were Oaktree Specialty Lending's earnings last quarter?

Oaktree Specialty Lending Co. (NASDAQ:OCSL) released its earnings results on Tuesday, November, 16th. The credit services provider reported $0.16 EPS for the quarter, beating the consensus estimate of $0.15 by $0.01. Oaktree Specialty Lending had a net margin of 143.41% and a trailing twelve-month return on equity of 8.87%. During the same period in the previous year, the company earned $0.17 EPS.
View Oaktree Specialty Lending's earnings history.

How often does Oaktree Specialty Lending pay dividends? What is the dividend yield for Oaktree Specialty Lending?

Oaktree Specialty Lending announced a quarterly dividend on Wednesday, November 17th. Shareholders of record on Wednesday, December 15th will be paid a dividend of $0.155 per share on Friday, December 31st. This represents a $0.62 annualized dividend and a yield of 8.52%. The ex-dividend date is Tuesday, December 14th. This is a positive change from Oaktree Specialty Lending's previous quarterly dividend of $0.15.
View Oaktree Specialty Lending's dividend history.

Is Oaktree Specialty Lending a good dividend stock?

Oaktree Specialty Lending pays an annual dividend of $0.58 per share and currently has a dividend yield of 7.89%. OCSL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Oaktree Specialty Lending has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio of Oaktree Specialty Lending is 31.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, Oaktree Specialty Lending will have a dividend payout ratio of 92.06% in the coming year. This indicates that Oaktree Specialty Lending may not be able to sustain their current dividend.
View Oaktree Specialty Lending's dividend history.

What price target have analysts set for OCSL?

3 brokerages have issued 12 month price objectives for Oaktree Specialty Lending's shares. Their forecasts range from $7.25 to $8.50. On average, they expect Oaktree Specialty Lending's share price to reach $7.75 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Oaktree Specialty Lending or view top-rated stocks among Wall Street analysts.

Who are Oaktree Specialty Lending's key executives?

Oaktree Specialty Lending's management team includes the following people:

• Armen Panossian, Chief Executive & Investment Officer
• Matt Pendo, President & Chief Operating Officer
• Mel Carlisle, Chief Financial Officer & Treasurer
• Kimberly Larin, Chief Compliance Officer
• Brian Thomas Walter, Managing Director & Head-Institutional Products

Who are some of Oaktree Specialty Lending's key competitors?

Some companies that are related to Oaktree Specialty Lending include BlackRock (BLK), Bank of New York Mellon (BK), T. Rowe Price Group (TROW), State Street (STT), Ameriprise Financial (AMP), Northern Trust (NTRS), Franklin Resources (BEN), Invesco (IVZ), Ares Capital (ARCC), SEI Investments (SEIC), Affiliated Managers Group (AMG), Cohen & Steers (CNS), Prospect Capital (PSEC), Main Street Capital (MAIN) and Golub Capital BDC (GBDC).
View all of OCSL's competitors.

What other stocks do shareholders of Oaktree Specialty Lending own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oaktree Specialty Lending investors own include Prospect Capital (PSEC), Energy Transfer (ET), AGNC Investment (AGNC), Annaly Capital Management (NLY), Ready Capital (RC), Ares Capital (ARCC), AT&T (T), PennantPark Investment (PNNT), PhenixFIN (MCC) and New Residential Investment (NRZ).

What is Oaktree Specialty Lending's stock symbol?

Oaktree Specialty Lending trades on the NASDAQ under the ticker symbol "OCSL."

Who are Oaktree Specialty Lending's major shareholders?

Oaktree Specialty Lending's stock is owned by a number of retail and institutional investors. Top institutional investors include River Road Asset Management LLC (3.47%), Private Management Group Inc. (3.19%), Ares Management LLC (2.83%), Bruni J V & Co. Co. (2.49%), Oaktree Capital Management LP (2.49%) and Rivernorth Capital Management LLC (1.68%). Company insiders that own Oaktree Specialty Lending stock include Armen Panossian, Craig A Jacobson, Deborah Ann Gero, Leonard M Tannenbaum, Leonard M Tannenbaum, Mathew Pendo, Melvin Carlisle and Richard Ruben.
View institutional ownership trends for Oaktree Specialty Lending.

Which major investors are selling Oaktree Specialty Lending stock?

OCSL stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Rivernorth Capital Management LLC, River Road Asset Management LLC, TCW Group Inc., Centaurus Financial Inc., LSV Asset Management, Van ECK Associates Corp, and Private Management Group Inc..
View insider buying and selling activity for Oaktree Specialty Lending or view top insider-selling stocks.

Which major investors are buying Oaktree Specialty Lending stock?

OCSL stock was purchased by a variety of institutional investors in the last quarter, including Oaktree Capital Management LP, Millennium Management LLC, Ares Management LLC, Rezny Wealth Management Inc., Two Sigma Investments LP, BlackRock Inc., Comerica Bank, and Navis Wealth Advisors LLC. Company insiders that have bought Oaktree Specialty Lending stock in the last two years include Armen Panossian, Craig A Jacobson, Deborah Ann Gero, Mathew Pendo, Melvin Carlisle, and Richard Ruben.
View insider buying and selling activity for Oaktree Specialty Lending or or view top insider-buying stocks.

How do I buy shares of Oaktree Specialty Lending?

Shares of OCSL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oaktree Specialty Lending's stock price today?

One share of OCSL stock can currently be purchased for approximately $7.28.

How much money does Oaktree Specialty Lending make?

Oaktree Specialty Lending has a market capitalization of $1.31 billion and generates $143.13 million in revenue each year. The credit services provider earns $39.22 million in net income (profit) each year or $1.82 on an earnings per share basis.

What is Oaktree Specialty Lending's official website?

The official website for Oaktree Specialty Lending is www.oaktreespecialtylending.com.

Where are Oaktree Specialty Lending's headquarters?

Oaktree Specialty Lending is headquartered at 333 SOUTH GRAND AVENUE 28TH FLOOR, LOS ANGELES CA, 90071.

How can I contact Oaktree Specialty Lending?

Oaktree Specialty Lending's mailing address is 333 SOUTH GRAND AVENUE 28TH FLOOR, LOS ANGELES CA, 90071. The credit services provider can be reached via phone at (213) 830-6300, via email at [email protected], or via fax at 203-681-3879.